Myomo Inc
myomo.comMyomo Inc (NYSE American: MYO) is a medical device company that designs and commercializes powered arm braces for people with neurological disorders and upper-limb paralysis. Revenue comes from direct sales of the MyoPro product line, with reimbursement primarily through Medicare and private insurance payers. The MyoPro Motion W (HCPCS code L8701) and MyoPro Motion G (HCPCS code L8702) are the core products, with CMS-set fees updated to approximately $34,970 and $68,800 respectively, effective January 1, 2025. An enhanced version, the MyoPro 2x, was introduced in the United States on April 30, 2025. Manufacturing is outsourced to Cogmedix. Myomo completed its IPO in June 2017 and is headquartered in Burlington, MA. The company reported a net loss of approximately $15.6 million for the year ended December 31, 2025, and carries a secured loan from Avenue backed by all company assets. Myomo holds CE mark authorization allowing sales in the European Union.
Products & Services
MyoPro Motion W (multi-articulated non-powered wrist brace), MyoPro Motion G (powered grasp device for severely weakened or clenched hands), and MyoPro 2x (enhanced flagship version introduced April 30, 2025 in the United States).
Revenue Model
Transactional device sales, with pricing tied to CMS fee schedules for HCPCS codes L8701 (MyoPro Motion W, approximately $34,970 effective January 1, 2025) and L8702 (MyoPro Motion G, approximately $68,800 effective January 1, 2025). Reimbursement flows through Medicare and private insurance payers.
Customers & Markets
Patients with neurological disorders and upper-limb paralysis, including stroke survivors. Reimbursement payers include Medicare and private insurers. End market is the powered orthotic device segment within durable medical equipment.
Geographic Exposure
Primary market is the United States, with CE mark authorization enabling sales in the European Union. EU data transfer obligations under GDPR are a noted compliance consideration.
Financial Snapshot
Loading...
